Related Experiment Video
Updated: Jul 15, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical
Deborah A Taira1, Todd B Seto, Richard Siegrist
1Harvard Clinical Research Institute, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston 02215, USA.
Background:
In reporting economic evaluations of clinical trials, results are often stated without a description of the methodology used to derive the cost estimates. We compared methods for measuring costs from multicenter clinical trials to determine the extent to which the methodology affects results.
Methods:
Patient-level data (n = 1849) from 3 multicenter clinical trials of percutaneous coronary revascularization were used to compare 4 methods of estimating costs: 1) hospital charges; 2) hospital charges converted to costs by use of hospital-level cost-to-charge ratios; 3) hospital charges converted to costs by use of department-level cost-to-charge ratios; 4) itemized catheterization laboratory costs with nonprocedural hospital costs generated from department-level cost-to-charge ratios.
Results:
The method used to approximate costs did not affect the main results of the economic comparisons for any of the trials. The magnitude of the cost estimates and the cost differences between treatment groups varied considerably by method, however. Charges were approximately twice as high as hospital cost estimates. At the patient level, costs generated by use of method 1 were within 10% of those generated by use of method 4 for only 5% of patients, compared with 34% and 22% of patients with methods 2 and 3, respectively. Only method 3 produced estimates of between-group cost differences that were consistently within $500 of the reference standard.
Conclusion:
Cost estimates derived from clinical trials in the cardiovascular arena vary substantially according to accounting methodology. Thus, in reporting the results of economic analyses, a detailed description of cost derivation is necessary, particularly when the absolute magnitude of the cost estimates is important to clinical decision-making or policy-level recommendations. For the purposes of group-level comparisons, conversion of hospital charges to costs on the basis of department-level cost-to-charge ratios appears to represent a reasonable compromise between accuracy and ease of implementation.
More Related Videos
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Bioequivalence of Drugs: Drugs with Multiple Indications
Hazard Ratio
For example, in a clinical trial evaluating a...